Tagged with Europe,

Pharma Olivier Pilley, French GM of the Swiss-American biotech company with a pioneering computational approach to anti-cancer therapies, presents ARIAD’s fascinating R&D model, his optimistic assessment of the competitiveness of the French clinical research environment as well as his personal motivations for working in a rapidly growing biotech company. ARIAD’s niche is…

Pharma Massimo Scaccabarozzi, President of Farmindustria, talks about the potential of the pharmaceutical industry in Italy, the changes which need implementing to realize that potential and his vision for the industry’s future. Massimo, first of all congratulations on your third term as President of Farmindustria. What has been you proudest achievement…

Pharma Multinationals have struggled to adapt their Romanian strategies, but the local production sector appears to be flourishing. Much of this impetus relates directly to EU accession and the harmonization of manufacturing standards. “Initially, it was difficult to enact the transition, because the authorities handed us strict deadlines to make ourselves…

Romania No one can accuse the Romanian government of being lethargic when it comes to healthcare reform. After an unprecedented seven years of zero new molecules being admitted to the state reimbursement list, the pharma industry has suddenly been subjected to a whirlwind of radical refashioning and legislatory upheaval. “The industry…

Romania Once touted by the IMS as one of the “fast followers” among the world’s “pharmerging” nations and feted by the international investor community in the wake of EU accession, Romania’s pharmaceutical industry appears resurgent once more after a number of years on the back burner. In 2014, Romania’s market size…

Pharma The director of GEMME reveals how the French generics market is young in comparison to other European countries – where generics were on the market twenty years before they became available in France, how today the French Ministry of Health is sending a clear signal about the importance of generics…

Holland In a market under strong pressures to contain costs, launching innovative products in a crowded market can be a challenge. Novo Nordisk GM Sanne Groenemeijer believes his organization’s willingness to try various solutions has helped them to maintain their dominant position as the market leader in diabetes. Since you took…

ireland Mr. Mazeman, can you please begin by offering a brief overview of your career to date? I am a French pharmacist by training, with expertise in pharmacology. I have worked for Servier for my entire career. I started in the industry as a medical representative for the company. I went…